Cytosorbents FY2024 EPS Forecast Lowered by HC Wainwright

Cytosorbents Co. (NASDAQ:CTSO) – Stock analysts at HC Wainwright lowered their FY2024 EPS estimates for shares of Cytosorbents in a report issued on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings of ($0.30) per share for the year, down from their prior estimate of ($0.29). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The business had revenue of $9.89 million during the quarter, compared to analyst estimates of $9.73 million. During the same period in the prior year, the business posted ($0.14) earnings per share.

Several other analysts also recently weighed in on CTSO. EF Hutton Acquisition Co. I upgraded Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th. StockNews.com started coverage on shares of Cytosorbents in a research note on Sunday, November 10th. They issued a “hold” rating on the stock.

Cytosorbents Trading Up 2.6 %

NASDAQ CTSO opened at $0.95 on Thursday. The stock has a 50-day moving average of $1.13 and a 200-day moving average of $1.01. The company has a current ratio of 1.97, a quick ratio of 1.71 and a debt-to-equity ratio of 1.06. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $2.15. The firm has a market cap of $51.94 million, a PE ratio of -2.64 and a beta of 0.56.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Atomi Financial Group Inc. bought a new stake in shares of Cytosorbents in the 3rd quarter worth approximately $51,000. CM Management LLC boosted its holdings in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares in the last quarter. Sargent Investment Group LLC increased its position in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the period. Finally, Avenir Corp increased its position in Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares during the period. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.